nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—UGT2B7—Mycophenolic acid—systemic scleroderma	0.139	0.184	CbGbCtD
Ezetimibe—UGT1A1—Mycophenolic acid—systemic scleroderma	0.12	0.159	CbGbCtD
Ezetimibe—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.0777	0.103	CbGbCtD
Ezetimibe—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0671	0.0887	CbGbCtD
Ezetimibe—ABCG2—Leflunomide—systemic scleroderma	0.0598	0.0789	CbGbCtD
Ezetimibe—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.0465	0.0614	CbGbCtD
Ezetimibe—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0408	0.0539	CbGbCtD
Ezetimibe—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0369	0.0488	CbGbCtD
Ezetimibe—ABCC3—Methotrexate—systemic scleroderma	0.036	0.0476	CbGbCtD
Ezetimibe—ABCB1—Lisinopril—systemic scleroderma	0.0226	0.0298	CbGbCtD
Ezetimibe—SLCO1B1—Methotrexate—systemic scleroderma	0.0186	0.0246	CbGbCtD
Ezetimibe—ABCB1—Captopril—systemic scleroderma	0.0169	0.0223	CbGbCtD
Ezetimibe—ABCC2—Methotrexate—systemic scleroderma	0.0164	0.0216	CbGbCtD
Ezetimibe—ABCG2—Methotrexate—systemic scleroderma	0.0148	0.0196	CbGbCtD
Ezetimibe—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0133	0.0176	CbGbCtD
Ezetimibe—ABCB1—Prednisone—systemic scleroderma	0.0106	0.0141	CbGbCtD
Ezetimibe—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00798	0.0105	CbGbCtD
Ezetimibe—CYP3A4—Prednisone—systemic scleroderma	0.00638	0.00842	CbGbCtD
Ezetimibe—ABCG5—digestive system—systemic scleroderma	0.00542	0.113	CbGeAlD
Ezetimibe—ABCB1—Methotrexate—systemic scleroderma	0.00534	0.00705	CbGbCtD
Ezetimibe—NPC1L1—digestive system—systemic scleroderma	0.0051	0.106	CbGeAlD
Ezetimibe—ABCG8—digestive system—systemic scleroderma	0.00483	0.101	CbGeAlD
Ezetimibe—SOAT1—connective tissue—systemic scleroderma	0.00242	0.0503	CbGeAlD
Ezetimibe—ANPEP—connective tissue—systemic scleroderma	0.00231	0.0481	CbGeAlD
Ezetimibe—SOAT1—smooth muscle tissue—systemic scleroderma	0.00221	0.046	CbGeAlD
Ezetimibe—UGT1A3—digestive system—systemic scleroderma	0.00216	0.0449	CbGeAlD
Ezetimibe—ANPEP—smooth muscle tissue—systemic scleroderma	0.00212	0.044	CbGeAlD
Ezetimibe—ANPEP—skin of body—systemic scleroderma	0.00209	0.0435	CbGeAlD
Ezetimibe—UGT2B15—digestive system—systemic scleroderma	0.00203	0.0423	CbGeAlD
Ezetimibe—SOAT1—digestive system—systemic scleroderma	0.00175	0.0363	CbGeAlD
Ezetimibe—ANPEP—digestive system—systemic scleroderma	0.00167	0.0348	CbGeAlD
Ezetimibe—SOAT1—tendon—systemic scleroderma	0.00166	0.0346	CbGeAlD
Ezetimibe—ANPEP—tendon—systemic scleroderma	0.00159	0.0331	CbGeAlD
Ezetimibe—SOAT1—lung—systemic scleroderma	0.00146	0.0304	CbGeAlD
Ezetimibe—ANPEP—lung—systemic scleroderma	0.0014	0.029	CbGeAlD
Ezetimibe—UGT2B7—digestive system—systemic scleroderma	0.00124	0.0258	CbGeAlD
Ezetimibe—UGT1A1—digestive system—systemic scleroderma	0.00105	0.0219	CbGeAlD
Ezetimibe—SLCO1B1—digestive system—systemic scleroderma	0.000878	0.0183	CbGeAlD
Ezetimibe—ABCC3—digestive system—systemic scleroderma	0.000833	0.0173	CbGeAlD
Ezetimibe—ABCC3—lung—systemic scleroderma	0.000695	0.0145	CbGeAlD
Ezetimibe—ABCC2—digestive system—systemic scleroderma	0.000665	0.0138	CbGeAlD
Ezetimibe—ABCB1—blood vessel—systemic scleroderma	0.000646	0.0134	CbGeAlD
Ezetimibe—ABCC2—tendon—systemic scleroderma	0.000633	0.0132	CbGeAlD
Ezetimibe—ABCG2—lung—systemic scleroderma	0.000405	0.00843	CbGeAlD
Ezetimibe—CYP3A4—digestive system—systemic scleroderma	0.000338	0.00703	CbGeAlD
Ezetimibe—ANPEP—Metabolism of Angiotensinogen to Angiotensins—ACE—systemic scleroderma	0.000282	0.186	CbGpPWpGaD
Ezetimibe—ABCB1—digestive system—systemic scleroderma	0.000239	0.00498	CbGeAlD
Ezetimibe—NPC1L1—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	0.000227	0.149	CbGpPWpGaD
Ezetimibe—Dyspepsia—Leflunomide—systemic scleroderma	0.000217	0.00112	CcSEcCtD
Ezetimibe—Pancreatitis—Prednisone—systemic scleroderma	0.000216	0.00112	CcSEcCtD
Ezetimibe—Vomiting—Mometasone—systemic scleroderma	0.000216	0.00112	CcSEcCtD
Ezetimibe—Dry mouth—Lisinopril—systemic scleroderma	0.000216	0.00112	CcSEcCtD
Ezetimibe—Feeling abnormal—Azathioprine—systemic scleroderma	0.000215	0.00111	CcSEcCtD
Ezetimibe—Rash—Mometasone—systemic scleroderma	0.000214	0.00111	CcSEcCtD
Ezetimibe—Asthenia—Captopril—systemic scleroderma	0.000214	0.00111	CcSEcCtD
Ezetimibe—Dermatitis—Mometasone—systemic scleroderma	0.000214	0.00111	CcSEcCtD
Ezetimibe—Decreased appetite—Leflunomide—systemic scleroderma	0.000214	0.00111	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000214	0.00111	CcSEcCtD
Ezetimibe—Confusional state—Lisinopril—systemic scleroderma	0.000213	0.0011	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000213	0.0011	CcSEcCtD
Ezetimibe—Headache—Mometasone—systemic scleroderma	0.000213	0.0011	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000212	0.0011	CcSEcCtD
Ezetimibe—Insomnia—Mycophenolic acid—systemic scleroderma	0.000212	0.0011	CcSEcCtD
Ezetimibe—Fatigue—Leflunomide—systemic scleroderma	0.000212	0.0011	CcSEcCtD
Ezetimibe—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000211	0.00109	CcSEcCtD
Ezetimibe—Pruritus—Captopril—systemic scleroderma	0.000211	0.00109	CcSEcCtD
Ezetimibe—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000211	0.00109	CcSEcCtD
Ezetimibe—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000211	0.00109	CcSEcCtD
Ezetimibe—Pain—Leflunomide—systemic scleroderma	0.00021	0.00109	CcSEcCtD
Ezetimibe—Constipation—Leflunomide—systemic scleroderma	0.00021	0.00109	CcSEcCtD
Ezetimibe—Infection—Lisinopril—systemic scleroderma	0.00021	0.00109	CcSEcCtD
Ezetimibe—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.00021	0.00109	CcSEcCtD
Ezetimibe—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000209	0.00108	CcSEcCtD
Ezetimibe—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000207	0.00107	CcSEcCtD
Ezetimibe—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000207	0.00107	CcSEcCtD
Ezetimibe—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000207	0.00107	CcSEcCtD
Ezetimibe—Body temperature increased—Azathioprine—systemic scleroderma	0.000206	0.00107	CcSEcCtD
Ezetimibe—Abdominal pain—Azathioprine—systemic scleroderma	0.000206	0.00107	CcSEcCtD
Ezetimibe—Skin disorder—Lisinopril—systemic scleroderma	0.000205	0.00106	CcSEcCtD
Ezetimibe—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000205	0.00106	CcSEcCtD
Ezetimibe—Diarrhoea—Captopril—systemic scleroderma	0.000204	0.00106	CcSEcCtD
Ezetimibe—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000204	0.00106	CcSEcCtD
Ezetimibe—Erectile dysfunction—Prednisone—systemic scleroderma	0.000203	0.00105	CcSEcCtD
Ezetimibe—Feeling abnormal—Leflunomide—systemic scleroderma	0.000203	0.00105	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000203	0.00105	CcSEcCtD
Ezetimibe—Fatigue—Mycophenolic acid—systemic scleroderma	0.000202	0.00105	CcSEcCtD
Ezetimibe—Nausea—Mometasone—systemic scleroderma	0.000202	0.00104	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000201	0.00104	CcSEcCtD
Ezetimibe—Pain—Mycophenolic acid—systemic scleroderma	0.000201	0.00104	CcSEcCtD
Ezetimibe—Constipation—Mycophenolic acid—systemic scleroderma	0.000201	0.00104	CcSEcCtD
Ezetimibe—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000201	0.00104	CcSEcCtD
Ezetimibe—ABCB1—lung—systemic scleroderma	0.0002	0.00416	CbGeAlD
Ezetimibe—Cough—Mycophenolate mofetil—systemic scleroderma	0.000198	0.00102	CcSEcCtD
Ezetimibe—Dizziness—Captopril—systemic scleroderma	0.000197	0.00102	CcSEcCtD
Ezetimibe—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000197	0.00102	CcSEcCtD
Ezetimibe—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000196	0.00101	CcSEcCtD
Ezetimibe—Urticaria—Leflunomide—systemic scleroderma	0.000195	0.00101	CcSEcCtD
Ezetimibe—Abdominal pain—Leflunomide—systemic scleroderma	0.000194	0.00101	CcSEcCtD
Ezetimibe—Body temperature increased—Leflunomide—systemic scleroderma	0.000194	0.00101	CcSEcCtD
Ezetimibe—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000193	0.001	CcSEcCtD
Ezetimibe—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000193	0.001	CcSEcCtD
Ezetimibe—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000193	0.001	CcSEcCtD
Ezetimibe—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000193	0.001	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000193	0.000999	CcSEcCtD
Ezetimibe—Breast disorder—Methotrexate—systemic scleroderma	0.000193	0.000998	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000193	0.000997	CcSEcCtD
Ezetimibe—Hypersensitivity—Azathioprine—systemic scleroderma	0.000192	0.000993	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000192	0.000993	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000993	CcSEcCtD
Ezetimibe—Insomnia—Lisinopril—systemic scleroderma	0.000191	0.000989	CcSEcCtD
Ezetimibe—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000988	CcSEcCtD
Ezetimibe—Paraesthesia—Lisinopril—systemic scleroderma	0.00019	0.000982	CcSEcCtD
Ezetimibe—Vomiting—Captopril—systemic scleroderma	0.00019	0.000982	CcSEcCtD
Ezetimibe—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000189	0.000978	CcSEcCtD
Ezetimibe—Dyspnoea—Lisinopril—systemic scleroderma	0.000188	0.000975	CcSEcCtD
Ezetimibe—Rash—Captopril—systemic scleroderma	0.000188	0.000974	CcSEcCtD
Ezetimibe—Dermatitis—Captopril—systemic scleroderma	0.000188	0.000973	CcSEcCtD
Ezetimibe—Headache—Captopril—systemic scleroderma	0.000187	0.000968	CcSEcCtD
Ezetimibe—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000966	CcSEcCtD
Ezetimibe—Dyspepsia—Lisinopril—systemic scleroderma	0.000186	0.000963	CcSEcCtD
Ezetimibe—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000186	0.00096	CcSEcCtD
Ezetimibe—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000186	0.00096	CcSEcCtD
Ezetimibe—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000185	0.000959	CcSEcCtD
Ezetimibe—Infection—Mycophenolate mofetil—systemic scleroderma	0.000184	0.000952	CcSEcCtD
Ezetimibe—Decreased appetite—Lisinopril—systemic scleroderma	0.000184	0.000951	CcSEcCtD
Ezetimibe—Eosinophilia—Methotrexate—systemic scleroderma	0.000183	0.000945	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000182	0.000944	CcSEcCtD
Ezetimibe—Fatigue—Lisinopril—systemic scleroderma	0.000182	0.000943	CcSEcCtD
Ezetimibe—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000182	0.00094	CcSEcCtD
Ezetimibe—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000181	0.000938	CcSEcCtD
Ezetimibe—Hypersensitivity—Leflunomide—systemic scleroderma	0.000181	0.000938	CcSEcCtD
Ezetimibe—Pancreatitis—Methotrexate—systemic scleroderma	0.000181	0.000936	CcSEcCtD
Ezetimibe—Constipation—Lisinopril—systemic scleroderma	0.000181	0.000936	CcSEcCtD
Ezetimibe—Pain—Lisinopril—systemic scleroderma	0.000181	0.000936	CcSEcCtD
Ezetimibe—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000931	CcSEcCtD
Ezetimibe—Diarrhoea—Azathioprine—systemic scleroderma	0.000178	0.000922	CcSEcCtD
Ezetimibe—Nausea—Captopril—systemic scleroderma	0.000177	0.000918	CcSEcCtD
Ezetimibe—Asthenia—Leflunomide—systemic scleroderma	0.000176	0.000913	CcSEcCtD
Ezetimibe—Feeling abnormal—Lisinopril—systemic scleroderma	0.000174	0.000902	CcSEcCtD
Ezetimibe—Pruritus—Leflunomide—systemic scleroderma	0.000174	0.000901	CcSEcCtD
Ezetimibe—Connective tissue disorder—Prednisone—systemic scleroderma	0.000174	0.000899	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000173	0.000895	CcSEcCtD
Ezetimibe—Dizziness—Azathioprine—systemic scleroderma	0.000172	0.000892	CcSEcCtD
Ezetimibe—ABCG8—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	0.000172	0.113	CbGpPWpGaD
Ezetimibe—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000171	0.000887	CcSEcCtD
Ezetimibe—Erectile dysfunction—Methotrexate—systemic scleroderma	0.00017	0.000879	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000169	0.000873	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000168	0.000872	CcSEcCtD
Ezetimibe—Asthenia—Mycophenolic acid—systemic scleroderma	0.000168	0.000871	CcSEcCtD
Ezetimibe—Diarrhoea—Leflunomide—systemic scleroderma	0.000168	0.000871	CcSEcCtD
Ezetimibe—Urticaria—Lisinopril—systemic scleroderma	0.000168	0.000869	CcSEcCtD
Ezetimibe—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000168	0.000867	CcSEcCtD
Ezetimibe—Body temperature increased—Lisinopril—systemic scleroderma	0.000167	0.000865	CcSEcCtD
Ezetimibe—Abdominal pain—Lisinopril—systemic scleroderma	0.000167	0.000865	CcSEcCtD
Ezetimibe—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000166	0.000861	CcSEcCtD
Ezetimibe—Pruritus—Mycophenolic acid—systemic scleroderma	0.000166	0.000859	CcSEcCtD
Ezetimibe—Vomiting—Azathioprine—systemic scleroderma	0.000166	0.000857	CcSEcCtD
Ezetimibe—ABCG5—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	0.000165	0.109	CbGpPWpGaD
Ezetimibe—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000855	CcSEcCtD
Ezetimibe—Infestation NOS—Methotrexate—systemic scleroderma	0.000165	0.000851	CcSEcCtD
Ezetimibe—Infestation—Methotrexate—systemic scleroderma	0.000165	0.000851	CcSEcCtD
Ezetimibe—Rash—Azathioprine—systemic scleroderma	0.000164	0.00085	CcSEcCtD
Ezetimibe—Dermatitis—Azathioprine—systemic scleroderma	0.000164	0.000849	CcSEcCtD
Ezetimibe—Flushing—Prednisone—systemic scleroderma	0.000164	0.000849	CcSEcCtD
Ezetimibe—Headache—Azathioprine—systemic scleroderma	0.000163	0.000845	CcSEcCtD
Ezetimibe—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000163	0.000844	CcSEcCtD
Ezetimibe—Dizziness—Leflunomide—systemic scleroderma	0.000163	0.000842	CcSEcCtD
Ezetimibe—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000161	0.000833	CcSEcCtD
Ezetimibe—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000161	0.000831	CcSEcCtD
Ezetimibe—Angiopathy—Prednisone—systemic scleroderma	0.00016	0.00083	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00016	0.000828	CcSEcCtD
Ezetimibe—Immune system disorder—Prednisone—systemic scleroderma	0.00016	0.000826	CcSEcCtD
Ezetimibe—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000158	0.00082	CcSEcCtD
Ezetimibe—Pain—Mycophenolate mofetil—systemic scleroderma	0.000158	0.00082	CcSEcCtD
Ezetimibe—Vomiting—Leflunomide—systemic scleroderma	0.000156	0.000809	CcSEcCtD
Ezetimibe—Alopecia—Prednisone—systemic scleroderma	0.000156	0.000808	CcSEcCtD
Ezetimibe—Hypersensitivity—Lisinopril—systemic scleroderma	0.000156	0.000806	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000156	0.000805	CcSEcCtD
Ezetimibe—Dizziness—Mycophenolic acid—systemic scleroderma	0.000155	0.000803	CcSEcCtD
Ezetimibe—Rash—Leflunomide—systemic scleroderma	0.000155	0.000803	CcSEcCtD
Ezetimibe—Dermatitis—Leflunomide—systemic scleroderma	0.000155	0.000802	CcSEcCtD
Ezetimibe—Mental disorder—Prednisone—systemic scleroderma	0.000155	0.000801	CcSEcCtD
Ezetimibe—Nausea—Azathioprine—systemic scleroderma	0.000155	0.000801	CcSEcCtD
Ezetimibe—Headache—Leflunomide—systemic scleroderma	0.000154	0.000798	CcSEcCtD
Ezetimibe—Malnutrition—Prednisone—systemic scleroderma	0.000154	0.000796	CcSEcCtD
Ezetimibe—Erythema—Prednisone—systemic scleroderma	0.000154	0.000796	CcSEcCtD
Ezetimibe—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000153	0.00079	CcSEcCtD
Ezetimibe—Asthenia—Lisinopril—systemic scleroderma	0.000152	0.000785	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000151	0.000784	CcSEcCtD
Ezetimibe—Pruritus—Lisinopril—systemic scleroderma	0.00015	0.000774	CcSEcCtD
Ezetimibe—Vomiting—Mycophenolic acid—systemic scleroderma	0.000149	0.000772	CcSEcCtD
Ezetimibe—Rash—Mycophenolic acid—systemic scleroderma	0.000148	0.000766	CcSEcCtD
Ezetimibe—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000148	0.000765	CcSEcCtD
Ezetimibe—Hepatitis—Methotrexate—systemic scleroderma	0.000148	0.000764	CcSEcCtD
Ezetimibe—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000147	0.000761	CcSEcCtD
Ezetimibe—Headache—Mycophenolic acid—systemic scleroderma	0.000147	0.000761	CcSEcCtD
Ezetimibe—Pharyngitis—Methotrexate—systemic scleroderma	0.000147	0.000759	CcSEcCtD
Ezetimibe—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000758	CcSEcCtD
Ezetimibe—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000758	CcSEcCtD
Ezetimibe—Nausea—Leflunomide—systemic scleroderma	0.000146	0.000756	CcSEcCtD
Ezetimibe—Diarrhoea—Lisinopril—systemic scleroderma	0.000145	0.000749	CcSEcCtD
Ezetimibe—Ill-defined disorder—Prednisone—systemic scleroderma	0.000143	0.000739	CcSEcCtD
Ezetimibe—Anaemia—Prednisone—systemic scleroderma	0.000142	0.000736	CcSEcCtD
Ezetimibe—Angioedema—Prednisone—systemic scleroderma	0.000141	0.000727	CcSEcCtD
Ezetimibe—Dizziness—Lisinopril—systemic scleroderma	0.00014	0.000723	CcSEcCtD
Ezetimibe—Erythema multiforme—Methotrexate—systemic scleroderma	0.00014	0.000723	CcSEcCtD
Ezetimibe—Nausea—Mycophenolic acid—systemic scleroderma	0.000139	0.000721	CcSEcCtD
Ezetimibe—Malaise—Prednisone—systemic scleroderma	0.000139	0.000718	CcSEcCtD
Ezetimibe—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000136	0.000706	CcSEcCtD
Ezetimibe—Vomiting—Lisinopril—systemic scleroderma	0.000134	0.000696	CcSEcCtD
Ezetimibe—Angiopathy—Methotrexate—systemic scleroderma	0.000134	0.000693	CcSEcCtD
Ezetimibe—Immune system disorder—Methotrexate—systemic scleroderma	0.000133	0.00069	CcSEcCtD
Ezetimibe—Rash—Lisinopril—systemic scleroderma	0.000133	0.00069	CcSEcCtD
Ezetimibe—Dermatitis—Lisinopril—systemic scleroderma	0.000133	0.000689	CcSEcCtD
Ezetimibe—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000133	0.000689	CcSEcCtD
Ezetimibe—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000133	0.000688	CcSEcCtD
Ezetimibe—Hypertension—Prednisone—systemic scleroderma	0.000133	0.000687	CcSEcCtD
Ezetimibe—Headache—Lisinopril—systemic scleroderma	0.000132	0.000685	CcSEcCtD
Ezetimibe—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000678	CcSEcCtD
Ezetimibe—Myalgia—Prednisone—systemic scleroderma	0.000131	0.000678	CcSEcCtD
Ezetimibe—Arthralgia—Prednisone—systemic scleroderma	0.000131	0.000678	CcSEcCtD
Ezetimibe—Alopecia—Methotrexate—systemic scleroderma	0.00013	0.000675	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00013	0.000673	CcSEcCtD
Ezetimibe—Discomfort—Prednisone—systemic scleroderma	0.000129	0.00067	CcSEcCtD
Ezetimibe—Mental disorder—Methotrexate—systemic scleroderma	0.000129	0.00067	CcSEcCtD
Ezetimibe—Malnutrition—Methotrexate—systemic scleroderma	0.000129	0.000665	CcSEcCtD
Ezetimibe—Erythema—Methotrexate—systemic scleroderma	0.000129	0.000665	CcSEcCtD
Ezetimibe—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000127	0.000656	CcSEcCtD
Ezetimibe—Nausea—Lisinopril—systemic scleroderma	0.000126	0.00065	CcSEcCtD
Ezetimibe—Anaphylactic shock—Prednisone—systemic scleroderma	0.000126	0.00065	CcSEcCtD
Ezetimibe—Infection—Prednisone—systemic scleroderma	0.000125	0.000645	CcSEcCtD
Ezetimibe—Back pain—Methotrexate—systemic scleroderma	0.000124	0.000644	CcSEcCtD
Ezetimibe—Nervous system disorder—Prednisone—systemic scleroderma	0.000123	0.000637	CcSEcCtD
Ezetimibe—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000634	CcSEcCtD
Ezetimibe—Skin disorder—Prednisone—systemic scleroderma	0.000122	0.000631	CcSEcCtD
Ezetimibe—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000119	0.000617	CcSEcCtD
Ezetimibe—Anaemia—Methotrexate—systemic scleroderma	0.000119	0.000615	CcSEcCtD
Ezetimibe—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000609	CcSEcCtD
Ezetimibe—Rash—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000604	CcSEcCtD
Ezetimibe—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000604	CcSEcCtD
Ezetimibe—Headache—Mycophenolate mofetil—systemic scleroderma	0.000116	0.0006	CcSEcCtD
Ezetimibe—Malaise—Methotrexate—systemic scleroderma	0.000116	0.0006	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000114	0.000592	CcSEcCtD
Ezetimibe—Insomnia—Prednisone—systemic scleroderma	0.000114	0.000588	CcSEcCtD
Ezetimibe—Paraesthesia—Prednisone—systemic scleroderma	0.000113	0.000583	CcSEcCtD
Ezetimibe—Cough—Methotrexate—systemic scleroderma	0.000112	0.000581	CcSEcCtD
Ezetimibe—Dyspepsia—Prednisone—systemic scleroderma	0.000111	0.000572	CcSEcCtD
Ezetimibe—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00011	0.000569	CcSEcCtD
Ezetimibe—Chest pain—Methotrexate—systemic scleroderma	0.000109	0.000566	CcSEcCtD
Ezetimibe—Arthralgia—Methotrexate—systemic scleroderma	0.000109	0.000566	CcSEcCtD
Ezetimibe—Myalgia—Methotrexate—systemic scleroderma	0.000109	0.000566	CcSEcCtD
Ezetimibe—Decreased appetite—Prednisone—systemic scleroderma	0.000109	0.000565	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000109	0.000563	CcSEcCtD
Ezetimibe—Fatigue—Prednisone—systemic scleroderma	0.000108	0.00056	CcSEcCtD
Ezetimibe—Discomfort—Methotrexate—systemic scleroderma	0.000108	0.00056	CcSEcCtD
Ezetimibe—Constipation—Prednisone—systemic scleroderma	0.000107	0.000556	CcSEcCtD
Ezetimibe—Confusional state—Methotrexate—systemic scleroderma	0.000106	0.000548	CcSEcCtD
Ezetimibe—ANPEP—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.000105	0.0695	CbGpPWpGaD
Ezetimibe—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000105	0.000543	CcSEcCtD
Ezetimibe—Infection—Methotrexate—systemic scleroderma	0.000104	0.000539	CcSEcCtD
Ezetimibe—Feeling abnormal—Prednisone—systemic scleroderma	0.000103	0.000535	CcSEcCtD
Ezetimibe—Nervous system disorder—Methotrexate—systemic scleroderma	0.000103	0.000533	CcSEcCtD
Ezetimibe—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000103	0.000532	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000103	0.000531	CcSEcCtD
Ezetimibe—Skin disorder—Methotrexate—systemic scleroderma	0.000102	0.000527	CcSEcCtD
Ezetimibe—Urticaria—Prednisone—systemic scleroderma	9.97e-05	0.000516	CcSEcCtD
Ezetimibe—Abdominal pain—Prednisone—systemic scleroderma	9.92e-05	0.000514	CcSEcCtD
Ezetimibe—Body temperature increased—Prednisone—systemic scleroderma	9.92e-05	0.000514	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.56e-05	0.000495	CcSEcCtD
Ezetimibe—Insomnia—Methotrexate—systemic scleroderma	9.49e-05	0.000491	CcSEcCtD
Ezetimibe—Paraesthesia—Methotrexate—systemic scleroderma	9.42e-05	0.000488	CcSEcCtD
Ezetimibe—Dyspnoea—Methotrexate—systemic scleroderma	9.35e-05	0.000484	CcSEcCtD
Ezetimibe—Hypersensitivity—Prednisone—systemic scleroderma	9.25e-05	0.000479	CcSEcCtD
Ezetimibe—Dyspepsia—Methotrexate—systemic scleroderma	9.24e-05	0.000478	CcSEcCtD
Ezetimibe—Decreased appetite—Methotrexate—systemic scleroderma	9.12e-05	0.000472	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Methotrexate—systemic scleroderma	9.06e-05	0.000469	CcSEcCtD
Ezetimibe—Fatigue—Methotrexate—systemic scleroderma	9.05e-05	0.000468	CcSEcCtD
Ezetimibe—Asthenia—Prednisone—systemic scleroderma	9.01e-05	0.000466	CcSEcCtD
Ezetimibe—Pain—Methotrexate—systemic scleroderma	8.97e-05	0.000464	CcSEcCtD
Ezetimibe—Pruritus—Prednisone—systemic scleroderma	8.88e-05	0.00046	CcSEcCtD
Ezetimibe—Feeling abnormal—Methotrexate—systemic scleroderma	8.65e-05	0.000447	CcSEcCtD
Ezetimibe—Diarrhoea—Prednisone—systemic scleroderma	8.59e-05	0.000445	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.58e-05	0.000444	CcSEcCtD
Ezetimibe—Urticaria—Methotrexate—systemic scleroderma	8.33e-05	0.000431	CcSEcCtD
Ezetimibe—Dizziness—Prednisone—systemic scleroderma	8.3e-05	0.00043	CcSEcCtD
Ezetimibe—Abdominal pain—Methotrexate—systemic scleroderma	8.29e-05	0.000429	CcSEcCtD
Ezetimibe—Body temperature increased—Methotrexate—systemic scleroderma	8.29e-05	0.000429	CcSEcCtD
Ezetimibe—Vomiting—Prednisone—systemic scleroderma	7.98e-05	0.000413	CcSEcCtD
Ezetimibe—Rash—Prednisone—systemic scleroderma	7.92e-05	0.00041	CcSEcCtD
Ezetimibe—Dermatitis—Prednisone—systemic scleroderma	7.91e-05	0.000409	CcSEcCtD
Ezetimibe—Headache—Prednisone—systemic scleroderma	7.86e-05	0.000407	CcSEcCtD
Ezetimibe—Hypersensitivity—Methotrexate—systemic scleroderma	7.73e-05	0.0004	CcSEcCtD
Ezetimibe—Asthenia—Methotrexate—systemic scleroderma	7.53e-05	0.00039	CcSEcCtD
Ezetimibe—Nausea—Prednisone—systemic scleroderma	7.46e-05	0.000386	CcSEcCtD
Ezetimibe—Pruritus—Methotrexate—systemic scleroderma	7.42e-05	0.000384	CcSEcCtD
Ezetimibe—ANPEP—Peptide hormone metabolism—ACE—systemic scleroderma	7.41e-05	0.0488	CbGpPWpGaD
Ezetimibe—Diarrhoea—Methotrexate—systemic scleroderma	7.18e-05	0.000372	CcSEcCtD
Ezetimibe—Dizziness—Methotrexate—systemic scleroderma	6.94e-05	0.000359	CcSEcCtD
Ezetimibe—Vomiting—Methotrexate—systemic scleroderma	6.67e-05	0.000345	CcSEcCtD
Ezetimibe—Rash—Methotrexate—systemic scleroderma	6.62e-05	0.000342	CcSEcCtD
Ezetimibe—Dermatitis—Methotrexate—systemic scleroderma	6.61e-05	0.000342	CcSEcCtD
Ezetimibe—Headache—Methotrexate—systemic scleroderma	6.57e-05	0.00034	CcSEcCtD
Ezetimibe—Nausea—Methotrexate—systemic scleroderma	6.23e-05	0.000323	CcSEcCtD
Ezetimibe—ANPEP—Cardiac Progenitor Differentiation—TGFB1—systemic scleroderma	3.33e-05	0.0219	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.24e-05	0.0213	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.46e-05	0.0162	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.46e-05	0.0162	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.36e-05	0.0156	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.86e-05	0.0123	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.79e-05	0.0118	CbGpPWpGaD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	1.56e-05	0.0102	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—HSPG2—systemic scleroderma	1.44e-05	0.0095	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—ACE—systemic scleroderma	1.4e-05	0.00921	CbGpPWpGaD
Ezetimibe—ABCG2—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	1.32e-05	0.00868	CbGpPWpGaD
Ezetimibe—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	1.21e-05	0.00796	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—CTGF—systemic scleroderma	1.09e-05	0.0072	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—HSPG2—systemic scleroderma	1.09e-05	0.0072	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	1.07e-05	0.00708	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—HSPG2—systemic scleroderma	1.05e-05	0.00693	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL13—systemic scleroderma	9.75e-06	0.00642	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—MMP1—systemic scleroderma	8.98e-06	0.00591	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	8.65e-06	0.0057	CbGpPWpGaD
Ezetimibe—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	8.35e-06	0.0055	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—CTGF—systemic scleroderma	8.29e-06	0.00546	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—CTGF—systemic scleroderma	7.98e-06	0.00525	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	7.84e-06	0.00516	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—CCL2—systemic scleroderma	7.3e-06	0.00481	CbGpPWpGaD
Ezetimibe—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	7.13e-06	0.00469	CbGpPWpGaD
Ezetimibe—ANPEP—Metabolism of proteins—MMP2—systemic scleroderma	6.95e-06	0.00457	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	6.46e-06	0.00425	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.3e-06	0.00415	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—HSPG2—systemic scleroderma	6.16e-06	0.00406	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	6.14e-06	0.00404	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	6.1e-06	0.00402	CbGpPWpGaD
Ezetimibe—UGT1A3—NRF2 pathway—TGFB1—systemic scleroderma	4.8e-06	0.00316	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.78e-06	0.00314	CbGpPWpGaD
Ezetimibe—NPC1L1—Metabolism—NOS3—systemic scleroderma	4.76e-06	0.00314	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.69e-06	0.00309	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—CTGF—systemic scleroderma	4.67e-06	0.00307	CbGpPWpGaD
Ezetimibe—ABCC3—NRF2 pathway—TGFB1—systemic scleroderma	4.08e-06	0.00269	CbGpPWpGaD
Ezetimibe—UGT2B7—NRF2 pathway—TGFB1—systemic scleroderma	4.08e-06	0.00269	CbGpPWpGaD
Ezetimibe—ABCG8—Metabolism—NOS3—systemic scleroderma	3.61e-06	0.00238	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.56e-06	0.00234	CbGpPWpGaD
Ezetimibe—ABCG5—Metabolism—NOS3—systemic scleroderma	3.47e-06	0.00229	CbGpPWpGaD
Ezetimibe—UGT1A1—NRF2 pathway—TGFB1—systemic scleroderma	3.32e-06	0.00218	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—HSPG2—systemic scleroderma	3.3e-06	0.00217	CbGpPWpGaD
Ezetimibe—ABCC2—NRF2 pathway—TGFB1—systemic scleroderma	3.24e-06	0.00213	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	3.2e-06	0.00211	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—HSPG2—systemic scleroderma	2.81e-06	0.00185	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—HSPG2—systemic scleroderma	2.81e-06	0.00185	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—CTGF—systemic scleroderma	2.5e-06	0.00165	CbGpPWpGaD
Ezetimibe—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	2.49e-06	0.00164	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—HSPG2—systemic scleroderma	2.28e-06	0.0015	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—CTGF—systemic scleroderma	2.13e-06	0.0014	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—CTGF—systemic scleroderma	2.13e-06	0.0014	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—HSPG2—systemic scleroderma	2.09e-06	0.00138	CbGpPWpGaD
Ezetimibe—UGT2B15—Metabolism—NOS3—systemic scleroderma	2.03e-06	0.00134	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—HSPG2—systemic scleroderma	1.93e-06	0.00127	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—CTGF—systemic scleroderma	1.73e-06	0.00114	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—CTGF—systemic scleroderma	1.58e-06	0.00104	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—CTGF—systemic scleroderma	1.47e-06	0.000965	CbGpPWpGaD
Ezetimibe—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.23e-06	0.000808	CbGpPWpGaD
Ezetimibe—UGT1A3—Metabolism—NOS3—systemic scleroderma	1.09e-06	0.000717	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.05e-06	0.000689	CbGpPWpGaD
Ezetimibe—ABCC3—Metabolism—NOS3—systemic scleroderma	9.26e-07	0.00061	CbGpPWpGaD
Ezetimibe—UGT2B7—Metabolism—NOS3—systemic scleroderma	9.26e-07	0.00061	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—CTGF—systemic scleroderma	7.93e-07	0.000522	CbGpPWpGaD
Ezetimibe—UGT1A1—Metabolism—NOS3—systemic scleroderma	7.52e-07	0.000495	CbGpPWpGaD
Ezetimibe—SLCO1B1—Metabolism—NOS3—systemic scleroderma	6.89e-07	0.000454	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—HSPG2—systemic scleroderma	6.44e-07	0.000424	CbGpPWpGaD
Ezetimibe—ABCG2—Metabolism—NOS3—systemic scleroderma	6.38e-07	0.00042	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—CTGF—systemic scleroderma	4.88e-07	0.000322	CbGpPWpGaD
Ezetimibe—ABCB1—Metabolism—NOS3—systemic scleroderma	3.45e-07	0.000227	CbGpPWpGaD
Ezetimibe—CYP3A4—Metabolism—NOS3—systemic scleroderma	2.13e-07	0.00014	CbGpPWpGaD
